CytomX Therapeutics Inc at B Riley Securities Oncology Conference (Virtual) Transcript
Good afternoon, everyone, and welcome to day 2 of the B. Riley Virtual Oncology Conference. I'd like to thank the audience for staying with us today. And it is my pleasure to introduce our next presenters from CytomX Therapeutics. We have with us here today, Chris Ogden, Senior Vice President, Finance and IR; and Sean McCarthy, Chairman and CEO.
Sean, please take it away.
Great. Thanks very much, and good afternoon, everyone. I'd like to thank the B. Riley team for the invitation to present today. It's really a pleasure to be here.
Before we begin, I would like to remind everyone that during this presentation, I will be making forward-looking statements. Important risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov.
In my presentation today, I'd like to give an overview of CytomX's business strategy and pipeline, including our outlook for 2023. It's been a very exciting few months for the company as we have
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
